Clinical Indication ID & Name
Mavacamten for treating symptomatic obstructive hypertrophic cardiomyopathy
Test Group
Specialties
Test code
R454.1
Test name
Mavacamten for treating symptomatic obstructive hypertrophic cardiomyopathy
Target genes
CYP2C19
Test scope
*2, *3 and *17 alleles
Test method/ technology
Targeted variant testing
Optimal Family Structure
n/a
Eligibility Criteria
Testing Criteria
Testing is available to patients with:
1. symptomatic obstructive hypertrophic cardiomyopathy who have a New York Heart Association class of 2 to 3 AND
2. are eligible for treatment with mavacamten in line with NICE TA 913 (where mavacamten is an add on to individually optimised standard care that includes beta blockers, non-dihydropyridine calcium-channel blockers or disopyramide, unless these are contraindicated).
Where in Pathway
At prescribing decision
Requests for this test will only be accepted from centres that are commissioned to prescribe Mavacamten
Commissioning group
n/a
Overlapping idications
n/a
Address for samples/request forms
Please refer to the test request form.
Contact with queries
Supporting documents
n/a
Education resources
n/a
Service updates
n/a
Request form download
Form not available, please contact us to enquire.
Consent record
See consent guidance in test request form
Sample requirements
Sample Storage and Volume Required: Perirpheral blood in an EDTA tube: Adult and children 4 ml, Infants (0-2 years) 1 ml or a DNA sample (3-5µg of purified DNA). Where it is not possible to collect peripheral blood we will accept a saliva sample (please contact the lab for specific details). Storage, sample packing and transportation: Blood should be stored at 4°C where possible. Send at room temperature by first class post or by courier. Patient/Clinician Instructions: N/A Factors affecting performance of test/interpretation of results: Clotted samples are unsuitable for DNA analysis. Blood Samples in incorrect anticoagulant tubes may be rejected.